急性リンパ性白血病治療薬の世界市場-2023年～2030年

市場概要

急性リンパ性白血病治療薬の世界市場規模は、2022年に29億米ドルに達し、2030年には45億米ドルに達すると予測され、予測期間2023～2030年のCAGRは5.8%で成長する見込みです。小児の白血病の増加と新規薬剤の臨床試験の増加が、急性リンパ性白血病治療薬の市場動向の需要を押し上げています。

BまたはTリンパ芽球の悪性腫瘍は急性リンパ性白血病（ALL）として知られており、未成熟で異常なリンパ球とその前駆細胞の抑制されない増殖を特徴とします。この過程は、最終的に骨髄成分や他のリンパ系臓器の置換を引き起こし、特徴的な病型となります。

急性リンパ性白血病治療薬の市場範囲は、標的薬・免疫療法、放射線療法、化学療法、幹細胞移植などの療法からなり、急性リンパ性白血病治療薬の市場シェアを拡大しています。急性リンパ性白血病治療薬の世界市場は、研究開発の増加を含む要因の結果として拡大しており、各国における今後の医療承認もまた、急性リンパ性白血病治療薬市場の成長に明るい見通しを生み出しています。

市場力学

急性リンパ性白血病の発生率の増加が急性リンパ性白血病治療薬市場の成長を牽引

急性リンパ性白血病市場拡大の主な要因は、急性リンパ性白血病（ALL）の罹患率の増加です。毎年、男女10万人当たり約1.7人の新規患者が報告されています。米国がん協会の予測によると、2023年には国内で約6,540人の急性リンパ性白血病（ALL）が新たに発症し（子供と成人を含む）、その内訳は男性3,660人、女性2,880人、ALL関連死は約1,390人（男性700人、女性690人）です。

ALLを発症する確率が最も高いのは5歳以下の子供です。その後、リスクは20代半ばまで徐々に減少し、50歳前後で再び徐々に増加し始める。したがって、リンパ性白血病の症例の増加が急性リンパ性白血病治療薬市場を牽引しています。

研究開発の活発化がメーカーに有利な機会をもたらす

研究者により、将来的な洞察を提供し、治療へのより良いアプローチを提供する様々な開発が行われています。例えば、研究者らは、自己複製する白血病開始細胞の特徴をより詳しく知ることで、高リスクのB-ALLがどのようにして再発するのかをよりよく理解したいと考えました。これらの細胞がどの遺伝子によって活性化されるかを調べるため、研究チームは、移植研究とともに単一細胞RNA配列決定を利用し、細胞の増殖を調べた。

白血病は、白血病開始細胞が休眠状態にあるときに、解糖と低酸素シグナル伝達を抑制することによって制御されていることがわかっています。酸化的リン酸化国家に追いやられる過程で、細胞は白血病を引き起こす能力を失っています。したがって、これらの要因が急性リンパ性白血病治療薬市場規模の成長機会を生み出すことになります。

治療に伴う合併症が市場の成長を妨げる

支持療法は改善されたとはいえ、治療毒性によって引き起こされる死亡を防ぐことは依然として困難です。腫瘍崩壊症候群は、化学療法によってがん細胞が溶解し、カリウム、尿酸、カルシウム、リンなどの特定の内部要素が放出されることによって起こるもので、注意が必要です。これらの物質は高濃度で存在すると毒性を示し、腎不全を引き起こすことが多いです。

腫瘍崩壊症候群は、輸液やステロイドによる前処置で回避できることが多いです。しかし、そうなった場合の治療法は、集中的な輸液療法です。急性リンパ性白血病は治療後も再発することがあります。再発は21年後まで起こるかもしれないです。子供やその両親、家族に心理的サポートを与えるなど、幼い子供のがん治療に関連する追加的な懸念に対処することが極めて重要です。

COVID-19影響分析

COVID-19のパンデミックと世界各国でのロックダウンにより、あらゆる業種の企業の財務の健全性が影響を受けています。そのため、COVID-19公衆衛生緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、この地域の主要市場プレーヤーの数が少ないことから、世界の急性リンパ性白血病治療薬市場に与える影響は中程度と推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界の急性リンパ性白血病治療薬市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 政府および民間組織による取り組みの増加
    • 急性リンパ性白血病の罹患率の増加
  • 抑制要因
    • 治療に伴う合併症
  • 機会
    • 研究開発の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 治療タイプ別

• 治療薬
  • ペガスパラギナーゼ（オンカスパー）
  • シクロホスファミド（ネオサール）
  • ダウノルビシン（セルビジン）
  • ドキソルビシン（アドリアマイシン）
  • ネララビン（アラノン）
  • リツキシマブ（リツキサン）
  • ニロチニブ（タシグナ）
  • その他
• 手術療法
• その他

第8章 治療法別

• 標的薬・免疫療法
• 放射線療法
• 化学療法
• 幹細胞移植

第9章 細胞タイプ別

• フィラデルフィア染色体
• 前駆B細胞性ALL
• T細胞性ALL

第10章 エンドユーザー別

• 病院・病院薬局
• 放射線治療とオンライン薬局
• 外来手術センター
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東およびアフリカ
  • 主な地域別ダイナミクス

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Amgen Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Bristol-Myers Squibb
• Pfizer Inc.
• Novartis AG
• Sanofi
• Takeda Pharmaceutical Company Limited
• Spectrum Pharmaceuticals, Inc.
• SymBio Pharmaceuticals Limited
• Rare Disease Therapeutics, Inc.
• Erytech Pharma

第14章 付録

Market Overview

The Global Acute Lymphocytic Leukemia Therapeutics Market size reached US$ 2.9 billion in 2022 and is expected to reach US$ 4.5 billion by 2030 and is expected to grow with a CAGR of 5.8% during the forecast period 2023-2030. Increasing leukemia in children and the growing clinical trials for novel drugs are driving up demand for acute lymphocytic leukemia therapeutics market trends.

B or T lymphoblasts malignancy is known as Acute lymphocytic leukemia (ALL) that is characterized by unchecked proliferation of immature, abnormal lymphocytes and their progenitors. This process eventually results in the replacement of bone marrow components and other lymphoid organs, producing a distinctive disease pattern.

The acute lymphocytic leukemia therapeutics market scope comprises therapy as Targeted Drugs & Immunotherapy, Radiation Therapy, Chemotherapy and Stem Cell Transplantation, which has increased the acute lymphocytic leukemia therapeutics market share. The global market for acute lymphocytic leukemia therapeutics is expanding as a result of factors including increasing research and development and their upcoming medical approvals across countries are also creating a positive outlook for the acute lymphocytic leukemia therapeutics market growth.

Market Dynamics

An Increase in the Incidence of Acute Lymphocytic Leukemia Drives the Growth of the Acute Lymphocytic Leukemia Therapeutics Market

The primary driver of this market's expansion globally is the increasing incidence of acute lymphocytic leukemia (ALL). Approximately 1.7 new cases per 100,000 men and women are reported annually. According to projections from the American Cancer Society, there will be approximately 6,540 new instances of acute lymphocytic leukemia (ALL) in the country in 2023 (including kids and adults), comprising 3,660 male cases and 2,880 female cases and approximately 1,390 ALL-related deaths, including 700 male cases and 690 female cases.

Children under the age of 5 have the highest chance of developing ALL. The risk then gradually decreases until the mid-20s and then slowly starts to increase again around age 50. Hence, the growing cases of lymphocytic leukemia are driving the acute lymphocytic leukemia therapeutics market.

Rising Research and Development Creates Lucrative Opportunities for Manufacturers

Various developments are being done by the researchers that will provide future insight and will provide a better approach to treatment. For instance, researchers hoped to learn more about the characteristics of self-renewing leukemia-initiating cells to better understand how they cause high-risk B-ALL to relapse. To determine which genes these cells were activating at different times, they utilized single-cell RNA sequencing in conjunction with transplant studies to examine the cells' growth.

The leukemia was found to be controlled by suppressing glycolysis and hypoxia signaling in leukemia-initiating cells when they were dormant. In the process of being driven back to the oxidative phosphorylation nation, the cells lost their ability to cause leukemia. Thus these factors will create an opportunity for the growth of the acute lymphocytic leukemia therapeutics market size.

Complications Associated With the Treatment Will Hamper the Growth of the Market

Although supportive care has improved, it is still difficult to prevent death brought on by treatment toxicity. Tumor Lysis Syndrome, which happens when chemotherapy induces cancer cells to lyse and release certain internal elements like potassium, uric acid, calcium and phosphorus, should be kept an eye out for. These substances produce toxicity when present in high concentrations, which frequently results in renal failure.

Tumor Lysis Syndrome is often avoided by pretreatment with fluids and steroids. But if it does, the remedy is intensive fluid therapy. Acute lymphocytic leukemia might return even after treatment. Relapses might happen up to 21 years past. It is crucial to address additional concerns related to a young kid's cancer treatment, such as giving the kid, their parents and their family psychological support.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global acute lymphocytic leukemia therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global acute lymphocytic leukemia therapeutics market growth over the forecast period.

Segment Analysis

The global acute lymphocytic leukemia therapeutics market is segmented based on treatment type, therapy, cell type, distribution channel and region.

Philadelphia Chromosome From Cell Type Segment Accounts for 40.3% of Market Share Owing to Rising Novel Product Launches

Acute lymphoblastic leukemia (ALL), which has the Philadelphia chromosome (Ph+ ), makes up around one-fourth of adult ALL cases. It often has an aggressive clinical course, does not react well to conventional chemotherapy and is highly plausible. Ph+ ALL is a rapidly developing condition for which there are presently no front-line targeted therapies authorized in the United States.

A potent therapy that can prevent the emergence of challenging-to-treat mutations, which are linked to suboptimal long-term results, is urgently required. Since the invention of tyrosine kinase inhibitors (TKIs), the landscape of Ph+ ALL therapy has improved. The PhALLCON study compares ICLUSIG and imatinib in combination with low-intensity chemotherapy as a primary therapy for adult patients having newly diagnosed Ph+ ALL. It is a Phase 3 randomized, multinational, open-label multicenter experiment.

Geographical Analysis

North America Accounted For Approximately 41.3% Of the Market Share Owing to The Strong Presence Of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for acute lymphocytic leukemia therapeutics for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of acute lymphocytic leukemia therapeutics, which has increased the demand.

Rising new drugs for different types of lymphocytic leukemia will drive the market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of treatment approaches for acute lymphocytic leukemia, leading to the expansion of the market in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the acute lymphocytic leukemia therapeutics market include: Merck & Co. Inc., Pfizer Inc., Bristol-Myers Squibb, Novartis AG, Takeda Pharmaceutical Company Limited, Sanofi, Spectrum Pharmaceuticals, Inc., Rare Disease Therapeutics, Inc., SymBio Pharmaceuticals Limited and Erytech Pharma among others.

Why Purchase the Report?

• To visualize the global acute lymphocytic leukemia therapeutics market segmentation based on treatment type, therapy, cell type, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of acute lymphocytic leukemia therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Acute Lymphocytic Leukemia Therapeutics Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.

Target Audience 2023

• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Therapy
• 3.3. Snippet by Cell Type
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Initiatives Taken by the Government and Private Organizations
    • 4.1.1.2. The Growing Incidence of Acute Lymphocytic Leukemia
  • 4.1.2. Restraints
    • 4.1.2.1. Complications Associated with the Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Rising Research and Development
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Drugs
  • 7.2.1. Pegasparaginase (Oncaspar) *
    • 7.2.1.1. Introduction
    • 7.2.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.2. Cyclophosphamide (Neosar)
  • 7.2.3. Daunorubicin (Cerubidine)
  • 7.2.4. Doxorubicin (Adriamycin)
  • 7.2.5. Nelarabine (Arranon)
  • 7.2.6. Rituximab (Rituxan)
  • 7.2.7. Nilotinib (Tasigna)
  • 7.2.8. Others
• 7.3. Surgery
• 7.4. Others

8. By Therapy

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 8.1.2. Market Attractiveness Index, By Therapy
• 8.2. Targeted Drugs & Immunotherapy *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Radiation Therapy
• 8.4. Chemotherapy
• 8.5. Stem Cell Transplantation

9. By Cell Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
  • 9.1.2. Market Attractiveness Index, By Cell Type
• 9.2. Philadelphia Chromosome *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Precursor B-Cell ALL
• 9.4. T-Cell ALL

10. By End user

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 10.1.2. Market Attractiveness Index, By End User
• 10.2. Hospital & Hospital Pharmacy *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Radiation Therapy and Online Pharmacy
• 10.4. Ambulatory Surgical Centers
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. The U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. The U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan

Australia

• 11.5.7.4. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Amgen Inc. *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Bristol-Myers Squibb
• 13.3. Pfizer Inc.
• 13.4. Novartis AG
• 13.5. Sanofi
• 13.6. Takeda Pharmaceutical Company Limited
• 13.7. Spectrum Pharmaceuticals, Inc.
• 13.8. SymBio Pharmaceuticals Limited
• 13.9. Rare Disease Therapeutics, Inc.
• 13.10. Erytech Pharma

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us